MedPage Today on MSN6d
STRIDE: Semaglutide Shows It Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased ...
Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...
Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...
USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...
Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback